Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 2021

View Archived Issues

Mutations in TP73 cause lissencephaly and impaired mucociliary clearance

YishengBio cleared in UAE to conduct phase I study of PIKA recombinant COVID-19 vaccine

MUSK-targeting agonist antibody is protective against experimental congenital myasthenia

Kymera Therapeutics STAT3 degradation inducers demonstrate preclinical activity

Sumitomo Dainippon Pharma divulges 5-HT2A and/or 5-HT7 receptor antagonists

Positive topline data reported from phase II REDWOOD-HCM study of CK-274

Sitryx Therapeutics presents new NFE2L2 activators

Angex Pharmaceutical synthesizes new mTOR inhibitors

SRI International describes lipoxygenase inhibitors

iOnctura initiates clinical development of next-generation autotaxin inhibitor IOA-289

DSMB recommends continued treatment in phase II portion of OVATION 2 study with GEN-1

Prometheus initiates phase II ARTEMIS-UC study of PRA-023

Loss-of-function variant in SUV39H2 identified in autism spectrum disorder

VX-548 enters phase II development for the treatment of acute pain

CXCL9 levels predict future cardiac aging and vascular dysfunction

GS-9822 retargets integration sites and induces deep latent state in vitro

Modulation of STAT pathway with HODHBt improves NK cell cytotoxicity

Acumen initiates phase I study of ACU-193 in mild cognitive impairment or mild Alzheimer's

Lenacapavir confers viral suppression by week 16 in HIV-infected patients

Grant supports clinical development of ISA-104 for chronic hepatitis B

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...